Exosomal miR-1246 in serum as a potential biomarker for early diagnosis of gastric cancer
- 27 Downloads
Gastric cancer (GC) patients are usually diagnosed in advanced stages which results in high mortality. This study aimed to identify novel circulating miRNAs as biomarkers for the early detection of GC.
Candidate miRNA was identified after integrated analysis of two Gene Expression Omnibus (GEO) datasets and clinical serum samples. Exosomes extracted were verified using transmission electron microscopy (TEM) and western blot. The expressions of miRNAs were tested through qRT-PCR. Receiver operating characteristic curve (ROC) analysis was used to explore the diagnostic utility of miRNAs. RNA pull-down assay was used to find RNA binding proteins (RBPs) which transport candidate miRNA into exosomes. Bioinformatics analysis of candidate miRNA was conducted using DAVID and Cytoscape.
After integrated analysis of two GEO datasets, six circulating miRNAs were found to be consistently upregulated in GC patients. Then, qRT-PCR demonstrated that serum miR-1246 was the one with the largest fold change. Studies in vitro revealed that elevated serum miR-1246 was tumor-derived by being packaged into exosomes with the help of ELAVL1. Thereafter, we discovered that exosomal miR-1246 expressions in serum could differentiate GC patients with TNM stage I from healthy controls (HCs) and patients with benign diseases (BDs) with area under the curve (AUC) of 0.843 and 0.811, respectively. Bioinformatics analysis revealed miR-1246, as a tumor suppressor in GC, could regulate several signaling pathways.
Circulating exosomal miR-1246 was a potential biomarker for the early diagnosis of GC.
KeywordsExosomes miR-1246 Gastric cancer Diagnosis Biomarker
Compliance with ethical standards
Conflict of interest
The authors report no conflicts of interest in this work.
This study was approved by the Research and Ethical Committee of The Second Affiliated Hospital of Nanjing Medical University.
Written informed consent was obtained from all participants
- 3.Carpelan-Holmstrom M, Louhimo J, Stenman UH et al (2002) CEA, CA 19–9 and CA 72–4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 22:2311–2316Google Scholar
- 4.Hundahl SA, Phillips JL, Menck HR (2000) The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 88:921–932Google Scholar
- 6.Newton AD, Datta J, Loaiza-Bonilla A et al (2015) Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol 6:534–543Google Scholar
- 40.Yuan D, Xu J, Wang J et al (2016) Extracellular miR-1246 promotes lung cancer cell proliferation and enhances radioresistance by directly targeting DR5. Oncotarget 7:32707–32722Google Scholar